Inducible nitric oxide synthase inhibitor SD-3651 reduces proteinuria in MRL/lpr mice deficient in the NOS2 gene

Journal of Investigative Medicine

Volumn 56, Issue 7, 2008, Pages 911-919

  Njoku, Chinedu ^a   Self, Sally E ^b   Ruiz, Philip ^c   Hofbauer, Ann F ^d   Gilkeson, Gary S ^a,d   Oates, Jim C ^a,d,e  

^a Children's Mercy Kansas City   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^e MSC 637 ^*  (United States)

Author keywords

Animal models; Enzyme inhibitors; Lupus nephritis; Nitric oxide; Nitric oxide synthase

Indexed keywords

ALBUMIN; DOUBLE STRANDED DNA ANTIBODY; IMMUNOGLOBULIN G; NITRIC OXIDE SYNTHASE INHIBITOR; SD 3651; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; DRUG DERIVATIVE; ENZYME INHIBITOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LYSINE; N(6) (1 IMINOETHYL)LYSINE; N(6)-(1-IMINOETHYL)LYSINE; NOS2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ARTICLE; CELL DAMAGE; CELL SWELLING; CONTROLLED STUDY; DRUG MECHANISM; ELECTRON MICROSCOPY; ENDOTHELIUM CELL; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME INHIBITION; GENE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOGLOBULIN DEPOSITION; INDUCIBLE NITRIC OXIDE SYNTHASE GENE; KIDNEY PARENCHYMA; MICROSCOPY; MOUSE; NONHUMAN; PODOCYTOPATHY; PROLIFERATIVE GLOMERULONEPHRITIS; PROTEINURIA; SERUM; URINE; WILD TYPE; ANIMAL; BLOOD; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; ENZYMOLOGY; FEMALE; GENETICS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MOUSE MUTANT; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE;

ANIMALIA; MURINAE; MUS;

ANIMALS; ANTIBODIES, ANTINUCLEAR; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; FEMALE; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; LUPUS NEPHRITIS; LYSINE; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED MRL LPR; MICE, KNOCKOUT; NITRIC OXIDE SYNTHASE TYPE II; PROTEINURIA;

EID: 58149152931     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181889e13     Document Type: Article

References (29)

1. Oates JC, Gilkeson GS. Nitric oxide in SLE. In: Tsokos GC, Gordon C, Smolen JS, eds. Systemic Lupus Erythe matosus: A Companion to Rheumatology. 1st ed. Philadelphia, PA: Mosby Elsevier; 2007.
2. Oates JC, Gilkeson GS. The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. Clin Immunol. 2006;121:243-250.
3. Weinberg JB, Granger DL, Pisetsky DS, et al. The role of nitric oxide in the pathogenesis of spontaneous murine autoimmune disease: increased nitric oxide production and nitric oxide synthase expression in MRL-lpr/lpr mice, and reduction of spontaneous glomerulonephritis and arthritis by orally administered NG-monomethyl-L-arginine. J Exp Med. 1994;179:651-660.
4. Reilly CM, Farrelly LW, Viti D, et al. Modulation of renal disease in MRL/lpr mice by pharmacologic inhibition of inducible nitric oxide synthase. Kidney Int. 2002;61: 839-846.
5. Oates JC, Ruiz P, Alexander A, et al. Effect of late modulation of nitric oxide production on murine lupus. Clin Immunol Immunopathol. 1997;83:86-92.
6. Gilkeson GS, Mudgett JS, Seldin MF, et al. Clinical and serologic manifestations of autoimmune disease in MRL-lpr/lpr mice lacking nitric oxide synthase type 2. J Exp Med. 1997;186:365-373.
7. Laubach VE, Shesely EG, Smithies O, et al. Mice lacking inducible nitric oxide synthase are not resistant to lipopolysaccharide-induced death. Proc Natl Acad Sci U S A. 1995;92:10688-10692.
8. Sekine H, Graham KL, Zhao S, et al. Role of MHC-linked genes in autoantigen selection and renal disease in a murine model of systemic lupus erythematosus. J Immunol. 2006;177:7423-7434.
9. Braman RS, Hendrix SA. Nanogram nitrite and nitrate determination in environmental and biological materials by vanadium (III) reduction with chemiluminescence detection. Anal Chem. 1989;61:2715-2718.
10. Benzie IF, Strain JJ. The ferric reducing ability of plasma (FRAP) as a measure of "antioxidant power": the FRAP assay. Anal Biochem. 1996;239:70-76.
11. McAnulty SR, McAnulty LS, Nieman DC, et al. Influence of carbohydrate ingestion on oxidative stress and plasma antioxidant potential following a 3 h run. Free Radic Res. 2003;37:835-840.
12. Hayat MA. Principles and techniques of electron microscopy; biological applications. New York, NY: Van Nostrand Reinhold Co; 1970.
13. Oates JC, Gilkeson GS. Nitric oxide induces apoptosis in spleen lymphocytes from MRL/lpr mice. J Investig Med. 2004;52:62-71.
14. Ruijter JM, Thygesen HH, Schoneveld OJ, et al. Factor correction as a tool to eliminate between-session variation in replicate experiments: application to molecular biology and retrovirology. Retrovirology. 2006;3:2.
15. Nagy G, Perl A. The role of nitric oxide in abnormal T cell signal transduction in systemic lupus erythematosus. Clin Immunol. 2006;118:145-151.
16. Boer R, Ulrich WR, Klein T, et al. The inhibitory potency and selectivity of arginine substrate site nitric-oxide synthase inhibitors is solely determined by their affinity toward the different isoenzymes. Mol Pharmacol. 2000; 58:1026-1034.
17. Mori M, Gotoh T. Regulation of nitric oxide production by argininemetabolicenzymes. BiochemBiophysResCommun. 2000;275:715-719.
18. Schmidt K, Klatt P, Mayer B. Uptake of nitric oxide synthase inhibitors by macrophage RAW 264.7 cells. Biochemical J. 1994;301:313-316.
19. Schwartz D, Schwartz IF, Gnessin E, et al. Differential regulation of glomerular arginine transporters (CAT-1 and CAT-2) in lipopolysaccharide-treated rats. Am J Physiol Renal Physiol. 2003;284:F788-F795.
20. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-530.
21. Chan TM, Cheng IK. Identification of endothelial cell membrane proteins that bind anti-DNA antibodies from patients with systemic lupus erythematosus by direct or indirect mechanisms. J Autoimmun. 1997;10:433-439.
22. Kruger AL, Peterson SJ, Schwartzman ML, et al. Up-regulation of heme oxygenase provides vascular protection in an animal model of diabetes through its antioxidant and antiapoptotic effects. J Pharmacol Exp Ther. 2006;319: 1144-1152.
23. Erusalimsky JD, Moncada S. Nitric oxide and mitochon-drial signaling: from physiology to pathophysiology. Arterioscler Thromb Vasc Biol. 2007;27:2524-2531.
24. Marshall SM. The podocyte: a potential therapeutic target in diabetic nephropathy? Curr Pharm Des. 2007;13: 2713-2720.
25. Lee EY, Chung CH, Kim JH, et al. Antioxidants ameliorate the expression of vascular endothelial growth factor mediated by protein kinase C in diabetic podocytes. Nephrol Dial Transplant. 2006;21:1496-1503.
26. Gill PS, Wilcox CS. NADPH oxidases in the kidney. Antioxid Redox Signal. 2006;8:1597-1607.
27. Han TS, Schwartz MM, Lewis EJ. Association of glomerular podocytopathy and nephrotic proteinuria in mesangial lupus nephritis. Lupus. 2006;15:71-75.
28. Kraft SW, Schwartz MM, Korbet SM, et al. Glomerular podocytopathy in patients with systemic lupus erythema-tosus. J Am Soc Nephrol. 2005;16:175-179.
29. Couser WG, Nangaku M. Cellular and molecular biology of membranous nephropathy. J Nephrol. 2006;19:699-705.